price up icon0.58%   +0.15
after-market  After Hours:  26.015  -0.015   -0.06%
Genmab ADR stock is currently priced at $26.03, with a 24-hour trading volume of 571.80K. It has seen a +0.58% increased in the last 24 hours and a -10.70% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $25.79 pivot point. If it approaches the $26.04 resistance level, significant changes may occur.
Previous Close:
24h Volume:
Market Cap:
Net Income/Loss:
P/E Ratio:
Net Cash Flow:
1W Performance:
1M Performance:
6M Performance:
1Y Performance:
1D Range:
52W Range:

Genmab ADR Stock (GMAB) Company Profile

Genmab ADR
45 70 20 27 28
Kalvebod Brygge 43, Copenhagen
Next Earnings Date
Latest SEC Filings
GMAB's Discussions on Twitter

Genmab ADR Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab ADR Stock (GMAB) Financials Data

Genmab ADR (GMAB) Revenue 2024

GMAB reported a revenue (TTM) of $2.58 billion for the quarter ending March 31, 2024, a +21.88% rise year-over-year.

Genmab ADR (GMAB) Net Income 2024

GMAB net income (TTM) was $794.60 million for the quarter ending March 31, 2024, a +10.17% increase year-over-year.

Genmab ADR (GMAB) Cash Flow 2024

GMAB recorded a free cash flow (TTM) of $781.65 million for the quarter ending March 31, 2024, a -11.30% decrease year-over-year.

Genmab ADR (GMAB) Earnings per Share 2024

GMAB earnings per share (TTM) was $1.2067 for the quarter ending March 31, 2024, a +10.37% growth year-over-year.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
price up icon 0.37%
price down icon 1.10%
price down icon 1.44%
price up icon 5.27%
price up icon 1.70%
Cap:     |  Volume (24h):